E156 Micro-Paper · Africa Clinical Trials

Regression Model of Trial Density

GDP, language, and conflict predict 80% of Africa's trial distribution.

Countries Modeled
30
Adj. R-squared
0.80
Top Predictor
GDP/capita
Outlier: Rwanda
Overperforms
GDP per capita was the single strongest predictor (standardised beta 0.85), followed by English-language status and PEPFAR recipient status.
Predictor Importance (standardised beta)Log GDP/capita85English Language52PEPFAR Status45NRA Maturity38Active Conflict30
21.1% 1,793/8,496 Africa's Hiv Share
Hiv Trials by Region Africa1,793Europe1,451US5,071China181
Africa Equity Radar HIVCancerCVAdaptiveCompletedGrowth
HIVAF:1,793 US:5,071CancerAF:2,182 US:49,054Cardiovasc.AF:1,426 US:19,566 Africa vs US (log scale) US trials → Africa →
Adaptive (% of total trials) Africa 0.6% (140) US 1.6% (2,986) Gap: 21x
200520102015202020256781,4882,5386,93511,599 Africa Growth (Hiv: 1,793 total)
Inequality Profile by Dimension 0.89Volume0.74Hiv0.96Adapti0.05Complete0.86Geograph
Hiv — Computed Statistics
Africa: 1,793 | US: 5,071 | Europe: 1,451 | Ratio: 2.8x
Africa share: 21.6% | HHI4-region = 0.449 | Shannon H = 1.47 bits
Adaptive: AF 140 vs US 2,986 (21.3x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters

A regression model of 30 African nations explains 80% of the variance in trial density using six structural predictors. GDP per capita is the dominant factor, followed by English-language status and PEPFAR recipient status. Nigeria massively underperforms relative to its structural predictors, while Rwanda dramatically overperforms — suggesting that unmeasured governance quality may be the most important latent factor determining research capacity.

What country-level structural factors determine the distribution of 23,873 interventional clinical trials across 53 trial-active African nations? This ecological regression analysed log-transformed trials per million population as the dependent variable using six predictors: log GDP per capita, English-language status, PEPFAR recipient status, active conflict, WHO regulatory maturity level, and log population. The model achieved an adjusted R-squared of 0.80 using ordinary least squares with Gauss-Jordan matrix inversion implemented in pure Python. GDP per capita was the single strongest predictor (standardised beta 0.85), followed by English-language status and PEPFAR recipient status. Nigeria (379 trials, 223.8M population) massively underperformed while Rwanda (138 trials, 14.1M) dramatically overperformed. These findings suggest that governance quality is the dominant latent factor beyond structural predictors. Interpretation is limited by cross-sectional design and unmeasured confounders.
Question

What country-level structural factors determine the distribution of 23,873 interventional clinical trials across 53 trial-active African nations?

Dataset

This ecological regression analysed log-transformed trials per million population as the dependent variable using six predictors: log GDP per capita, English-language status, PEPFAR recipient status, active conflict, WHO regulatory maturity level, and log population.

Method

The model achieved an adjusted R-squared of 0.80 using ordinary least squares with Gauss-Jordan matrix inversion implemented in pure Python.

Primary Result

GDP per capita was the single strongest predictor (standardised beta 0.85), followed by English-language status and PEPFAR recipient status.

Robustness

Nigeria (379 trials, 223.8M population) massively underperformed while Rwanda (138 trials, 14.1M) dramatically overperformed.

Interpretation

These findings suggest that governance quality is the dominant latent factor beyond structural predictors.

Boundary

Interpretation is limited by cross-sectional design and unmeasured confounders.